BridgeBio Pharma Inc. (NASDAQ:BBIO)’s traded shares stood at 1.69 million during the last session, with the company’s beta value hitting 0.57. At the close of trading, the stock’s price was $14.25, to imply a decrease of -2.20% or -$0.32 in intraday trading. The BBIO share’s 52-week high remains $19.94, putting it -39.93% down since that peak but still an impressive 65.05% since price per share fell to its 52-week low of $4.98. The company has a valuation of $2.37B, with an average of 7.62 million shares in intraday trading volume over the past 10 days and average of 2.57 million shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for BridgeBio Pharma Inc. (BBIO), translating to a mean rating of 1.60. Of 9 analyst(s) looking at the stock, 0 analyst(s) give BBIO a Sell rating. 1 of those analysts rate the stock as Overweight while 0 advise Hold as 8 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.85.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
BridgeBio Pharma Inc. (NASDAQ:BBIO) trade information
After registering a -2.20% downside in the last session, BridgeBio Pharma Inc. (BBIO) has traded red over the past five days. The stock hit a weekly high of 16.60 this Wednesday, 03/15/23, dropping -2.20% in its intraday price action. The 5-day price performance for the stock is -13.11%, and 22.95% over 30 days. With these gigs, the year-to-date price performance is 87.01%. Short interest in BridgeBio Pharma Inc. (NASDAQ:BBIO) saw shorts transact 18.65 million shares and set a 14.06 days time to cover.
Analysts on Wall Street suggest a consensus price target of $25.63, implying an increase of 44.4% to the stock’s current value. The extremes give us $18.00 and $32.00 for target low and target high price respectively. As such, BBIO has been trading -124.56% off suggested target high and -26.32% from its likely low.
BridgeBio Pharma Inc. (BBIO) estimates and forecasts
Looking at statistics comparing BridgeBio Pharma Inc. share performance against respective industry, we note that the company has outperformed competitors. BridgeBio Pharma Inc. (BBIO) shares are 28.26% up over the last 6 months, with its year-to-date growth rate higher than industry average at 17.68% against 5.90%. Revenue is forecast to grow 15.80% this quarter before jumping 37.00% for the next one. The rating firms project that company’s revenue will grow 15.20% compared to the previous financial year.
Revenue forecast for the current quarter as set by 10 analysts is $4.52 million. Meanwhile, for the quarter ending Mar 2023, a total of 6 analyst(s) estimate revenue growth to $5.04 million.Earnings reports from the last fiscal year show that sales brought in $12.89 million and $1.69 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -64.90% before jumping 197.50% in the following quarter.
BridgeBio Pharma Inc. has its next earnings report out between May 03 and May 08. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. BridgeBio Pharma Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
BridgeBio Pharma Inc. (NASDAQ:BBIO)’s Major holders
BridgeBio Pharma Inc. insiders hold 6.43% of total outstanding shares, with institutional holders owning 98.61% of the shares at 105.39% float percentage. In total, 98.61% institutions holds shares in the company, led by Kohlberg Kravis Roberts & Co. L.P. As of Sep 29, 2022, the company held over 31.06 million shares (or 20.78% of shares), all amounting to roughly $308.75 million.
The next major institution holding the largest number of shares is Viking Global Investors, L.P. with 26.62 million shares, or about 17.81% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $264.61 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the BridgeBio Pharma Inc. (BBIO) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 6.18 million shares. This is just over 4.13% of the total shares, with a market valuation of $47.08 million. Data from the same date shows that the other fund manager holds a little less at 3.15 million, or 2.10% of the shares, all valued at about 31.26 million.